Compile Data Set for Download or QSAR
Report error Found 15 Enz. Inhib. hit(s) with all data for entry = 10719
TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562057(US11396506, Compound 37)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562054(US11396506, Compound 32)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562060(US11396506, Compound 42)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562061(US11396506, Compound 43)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562059(US11396506, Compound 39)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562062(US11396506, Compound 44)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562063(US11396506, Compound 45)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562051(US11396506, Compound 8)
Affinity DataIC50: 50nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562056(US11396506, Compound 36)
Affinity DataIC50: 150nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562055(US11396506, Compound 34)
Affinity DataIC50: 150nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562064(US11396506, Compound 46)
Affinity DataIC50: 150nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562065(US11396506, Compound 47)
Affinity DataIC50: 150nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562058(US11396506, Compound 38)
Affinity DataIC50: 626nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562052(US11396506, Compound 24)
Affinity DataIC50: 626nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent

TargetIntegrin alpha-V/beta-6(Human)
Pliant Therapeutics

US Patent
LigandPNGBDBM562053(US11396506, Compound 30)
Affinity DataIC50: 626nMAssay Description:Microplates were coated with recombinant human integrin αVβ6 (2 μg/mL) in PBS (100 μL/well 25 OC, overnight). The coating solutio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2022
Entry Details
US Patent